 Receptors, OX40
"Receptors, OX40" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis family receptor with specificity for OX40 LIGAND. It is found on the surface of activated T-LYMPHOCYTES where it plays a role in enhancing cytokine production and proliferation of CD4-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D053262
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.350 D23.050.301.264.035.855 D23.101.100.110.855
|
| Concept/Terms |
Receptors, OX40- Receptors, OX40
- OX40 Receptors
- CD134 Antigen
- Antigen, CD134
- Tumor Necrosis Factor Receptor Superfamily, Member 4
- OX40 Receptor
- Receptor, OX40
- Receptors, Tumor Necrosis Factor, Member 4
- Antigens, CD134
- CD134 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Receptors, OX40".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- Receptors, OX40 [D12.776.543.750.705.852.760.350]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Receptors, OX40 [D23.050.301.264.035.855]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Receptors, OX40 [D23.101.100.110.855]
Below are MeSH descriptors whose meaning is more specific than "Receptors, OX40".
This graph shows the total number of publications written about "Receptors, OX40" by people in this website by year, and whether "Receptors, OX40" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, OX40" by people in Profiles.
-
Badeaux MD, Rolig AS, Agnello G, Enzler D, Kasiewicz MJ, Priddy L, Wiggins JF, Muir A, Sullivan MR, Van Cleef J, Daige C, Vander Heiden MG, Rajamanickam V, Wooldridge JE, Redmond WL, Rowlinson SW. Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth. Cancer Immunol Res. 2021 04; 9(4):415-429.
-
Rehage N, Davydova E, Conrad C, Behrens G, Maiser A, Stehklein JE, Brenner S, Klein J, Jeridi A, Hoffmann A, Lee E, Dianzani U, Willemsen R, Feederle R, Reiche K, Hackermüller J, Leonhardt H, Sharma S, Niessing D, Heissmeyer V. Binding of NUFIP2 to Roquin promotes recognition and regulation of ICOS mRNA. Nat Commun. 2018 01 19; 9(1):299.
-
Xiao X, Gong W, Demirci G, Liu W, Spoerl S, Chu X, Bishop DK, Turka LA, Li XC. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2012 Jan 15; 188(2):892-901.
-
Burrell BE, Lu G, Li XC, Bishop DK. OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade. J Immunol. 2009 Jan 01; 182(1):379-90.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|